News

Why Merck Is A Better Dividend Stock Than Gilead Sciences
Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...
G-Protein Coupled Receptor (GPCR) Targeting Technologies Market on the Rise
According to the latest study from BCC Research, the "G-Protein Coupled Receptor (GPCR) Targeting: Technologies and Global ...
Amphista Therapeutics announces achievement of a research milestone in its collaboration with Merck triggering a milestone payment
CRBN/VHL, Targeted Glue™ degraders for oncology and immunology indications Cambridge, UK, 16 July 2025 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in the discovery of ...